PF-5230895 - Emergent Biosolutions, Pfizer
J.P. Morgan Healthcare Conference (Emergent Biosolutions) - Jan 10, 2012 - Pfizer completed enrollment for SBI-087 P2 dose finding study in RA & completed dosing for P1 safety & PK study in SLE; Anticipated data from P2 dose regimen finding study in RA by Pfizer in H1 '12 
Anticipated P2 trial data • Enrollment completion
http://www.larvolonline.com/tlg/ccdb/EmergentBiosolutionsJPMorganJan10'12.pdf
 
Jan 10, 2012
 
SBI-087 -- -- -- Clinical development 2011 Accomplishments              - Completed enrollment for SBI-087 P2 dose finding study in RA (by Pfizer)              - Completed dosing for P1 safety and PK study in SLE (by Pfizer) 2012 Milestones             - Anticipated data from P2 dose regimen finding study in RA by Pfizer in H1 '12
 
9a7d0d24-e30c-4509-acbf-e1547ed37b64.jpg